Krystal Biotech Inc

KRYS's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

KRYS Growth rates comparisons

Looking into Krystal Biotech Inc growth rates, revenue grew by 16.65 % in the third quarter of 2025 from the same quarter a year ago. Ranking at No. 334

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 10.36 %

Krystal Biotech Inc 's net income grew by 192 % in third quarter of 2025 year on year, above company average,

• More on KRYS's Growth

KRYS's Valuation comparisons

Krystal Biotech Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Krystal Biotech Inc PEG ratio is at 0.11 Company is currently trading with Price to Cash flow multiple of 316.69 in trailing twelve-month period.

Company

29.93

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 15.82.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 7.04.

• More on KRYS's Valuation

Total Debt (Millions $)	-
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	2,573,552
Net Income/Employee (TTM) $	1,371,793
Receivable Turnover (TTM)	3.32
Tangible Book Value (Per Share $)	38.14

KRYS's Valuation comparisons

Company

29.93

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 15.82.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 7.04.

Krystal Biotech Inc Price to Book Ratio is at 5.19 lower than Industry Avg. of 2100.73. and higher than S&P 500 Avg. of 0.02

• More on KRYS's Valuation

• Market Capitalization (Millions $)	5,902
• Shares Outstanding (Millions)	30
• Employees	145
• Revenues (TTM) (Millions $)	373
• Net Income (TTM) (Millions $)	199
• Cash Flow (TTM) (Millions $)	19
• Capital Exp. (TTM) (Millions $)	-11
• Total Debt (Millions $)	-
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	2,573,552
• Net Income/Employee(TTM) $	1,371,793
• Receivable Turnover Ratio (TTM)	3.32
• Tangible Book Value (Per Share $)	38.14

• Market Capitalization (Millions $)	5,902
• Shares Outstanding (Millions)	30
• Employees	145
• Revenues (TTM) (Millions $)	373
• Net Income (TTM) (Millions $)	199
• Cash Flow (TTM) (Millions $)	19
• Capital Exp. (TTM) (Millions $)	-11

KRYS's Profitability Comparisons

Krystal Biotech Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in third quarter of 2025 to 42.3 % from 40.93 % in II. Quarter.

Krystal Biotech Inc net profit margin of 81.15 % is currently ranking no. 1 in Biotechnology & Pharmaceuticals industry, ranking no. 4 in Healthcare sector and number 33 in S&P 500.

Profitability by Segment
Total	81.15 %

	*Ratio*
• Capital Ratio (MRQ)	10.14
• Total Debt to Equity (MRQ)	-
• Tangible Leverage Ratio (MRQ)	0.09
• Asset Turnover Ratio (TTM)	0.32
• Inventory Turnover Ratio (TTM)	-

KRYS's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.